On 20 June, China's National Medical Products Administration (NMPA) approved Simcere Pharmaceutical's Quviviq (daridorexant) tablets for insomnia treatment. The dual orexin receptor antagonist (OX1R/OX2R) helps patients fall and stay asleep without next-day drowsiness. Originally developed by Idorsia, Simcere secured Greater China rights in 2022 for USD 50 million. Quviviq previously gained EU/US approvals and demonstrated efficacy in China Phase III trials. It's now listed as first-line therapy in China's 2023 insomnia treatment guidelines.